Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1601-1620 of 1,738 trials

Cardiac Arrest: Landiolol Treatment Study

We are testing whether adding landiolol can help patients who have had a cardiac arrest regain a stable heartbeat faster. This study will also look at overall survival and safety outcomes.

Cardiac Arrest and Ventricular Fibrillation6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Worsening Heart Failure: COR-1167 Treatment Study

We are testing a new medication for people with worsening heart failure to see how it affects symptoms and heart health. The study will also check the safety and tolerability of this treatment.

Worsening Heart Failure≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Riluzole for Spinocerebellar Ataxia Type 7

We are studying whether Riluzole can help patients with Spinocerebellar Ataxia type 7 maintain their stability in symptoms and visual function. This trial will also assess the safety and tolerability of the medication.

Spinocerebellar Ataxia Type 7 (SCA7)1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesInternal MedicineNeurology

Colorectal Cancer: Galunisertib and Capecitabine Study

We are investigating a new drug combination for patients with advanced colorectal cancer that hasn't responded to chemotherapy. The goal is to learn more about its safety and effectiveness in treating this condition.

Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Colorectal Cancer: FOLFIRI and Cetuximab Treatment

We are studying whether a combination of FOLFIRI and Cetuximab is effective for patients with advanced colorectal cancer who have specific genetic markers. This research aims to improve first-line treatment options for these patients.

Metastatic Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Locally Advanced Rectal Cancer: NeoAspMet Trial

We are studying whether adding aspirin or metformin to standard chemotherapy improves tumor response in patients with locally advanced rectal cancer. This trial aims to see if these treatments can lead to better outcomes compared to standard care.

Locally Advanced Rectal CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Advanced Solid Tumors: PM534 Treatment

We are testing a new drug called PM534 for patients with advanced solid tumors. The goal is to learn about its safety and how it may help in treating this condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Pleural Mesothelioma: Ivonescimab Treatment Study

We are evaluating ivonescimab for patients with relapsing pleural mesothelioma who have already been treated with immunotherapy and chemotherapy. The study aims to assess its safety and effectiveness as a potential new treatment option.

Pleural Mesothelioma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Hepatitis Delta: Brelovitug Treatment Study

We are studying a new medication, brelovitug, for people with chronic hepatitis delta infection. The trial aims to see if it works better than waiting for treatment and to evaluate its safety.

Hepatitis D>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatology

Gastric Cancer: Pre-operative Treatment with Capecitabine and Atezolizumab

We are studying a combination of chemotherapy and immunotherapy for patients with resectable gastric and GE-junction cancer. The goal is to see if this treatment is safe and effective in shrinking tumors before surgery.

Gastric Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology

TryptoBPH: Tryptophan for Benign Prostatic Hyperplasia

We are studying whether tryptophan can improve urinary symptoms in men with benign prostatic hyperplasia. The trial will also look at its effects on prostate size and quality of life.

Benign Prostatic Hyperplasia6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineUrology

Atopic Dermatitis: Investigational Compounds Study

We are evaluating new treatments for moderate to severe atopic dermatitis to see if they improve skin symptoms better than a placebo. The study also looks at the safety of these treatments.

Atopic Dermatitis3-6 monthsEfficacy phase (II)Investigational MedicinesAllergologyDermatology

Neuroblastoma: Innovative Stem Cell Transplant and Immunotherapy

We are studying a new stem cell transplant method followed by immunotherapy for children with relapsed or resistant high-risk neuroblastoma. This trial aims to evaluate the safety and effectiveness of this approach in improving treatment outcomes.

Neuroblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Tozorakimab for Uncontrolled Asthma

We are studying whether different doses of tozorakimab can help adults with uncontrolled asthma reduce severe attacks. This trial compares the medication to a placebo to evaluate its effectiveness and safety.

Asthma1-2 yearsEfficacy phase (II)Investigational MedicinesPartially RemoteAllergologyPulmonology

High-Risk Thyroid Cancer: Neoadjuvant Pembrolizumab Study

We are studying the effects of pembrolizumab as a pre-surgery treatment for patients with high-risk thyroid cancers. The goal is to see if it improves outcomes and understand how the body responds to this therapy.

Thyroid CancerEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Testosterone Gel for Improving Recovery in Critically Ill Patients

We are studying whether daily testosterone gel can enhance physical performance and recovery in men and women during critical illness. This trial compares the gel to a placebo to see if it helps patients recover better after ICU admission.

Invasive Mechanical VentilationEfficacy phase (II)Standard MedicinesCost ReimbursementEndocrinologyInternal Medicine

Ovarian Cancer: PARP Inhibitor with Cisplatin and Heat Therapy

We are studying a new treatment approach for ovarian cancer that combines a PARP inhibitor with cisplatin and heat during surgery. This trial aims to see if this combination improves outcomes for patients.

Fallopian Tube CancerOvarian CancerExtraovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)Gynecology and ObstetricsOncology

New T Cell Therapy for Pediatric Blood Cancers

We are testing a modified T cell treatment for children with relapsed or hard-to-treat B-cell leukemia and lymphoma. The study aims to evaluate safety and effectiveness in helping these patients achieve remission.

Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Advanced Solid Tumors: Testing IPN01195

We are studying a new medicine called IPN01195 to see how safe it is and what the best dose is for adults with advanced solid tumors. This trial aims to understand its effects on tumor activity and how it works in the body.

Advanced Solid Tumour3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncology

Alzheimer's Disease: MK-2214 Study

We are testing a new medication, MK-2214, in people with early Alzheimer's disease to see if it may slow the progression of brain changes. The study will also evaluate the safety of this treatment compared to a placebo.

Alzheimer's Disease>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology